Avalo Therapeutics Statistics
Total Valuation
AVTX has a market cap or net worth of $956.17 million. The enterprise value is $874.50 million.
| Market Cap | 956.17M |
| Enterprise Value | 874.50M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AVTX has 52.57 million shares outstanding. The number of shares has increased by 131.04% in one year.
| Current Share Class | 52.57M |
| Shares Outstanding | 52.57M |
| Shares Change (YoY) | +131.04% |
| Shares Change (QoQ) | +10.28% |
| Owned by Insiders (%) | 1.51% |
| Owned by Institutions (%) | 57.76% |
| Float | 40.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16,206.23 |
| Forward PS | n/a |
| PB Ratio | 6.56 |
| P/TBV Ratio | 16.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14,822.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.66, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.66 |
| Quick Ratio | 7.07 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -88.76% and return on invested capital (ROIC) is -51.52%.
| Return on Equity (ROE) | -88.76% |
| Return on Assets (ROA) | -41.50% |
| Return on Invested Capital (ROIC) | -51.52% |
| Return on Capital Employed (ROCE) | -89.66% |
| Weighted Average Cost of Capital (WACC) | 8.75% |
| Revenue Per Employee | $1,788 |
| Profits Per Employee | -$2.57M |
| Employee Count | 33 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AVTX has paid $169,000 in taxes.
| Income Tax | 169,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +279.12% in the last 52 weeks. The beta is 0.82, so AVTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +279.12% |
| 50-Day Moving Average | 15.68 |
| 200-Day Moving Average | 15.67 |
| Relative Strength Index (RSI) | 64.85 |
| Average Volume (20 Days) | 1,674,684 |
Short Selling Information
The latest short interest is 6.38 million, so 12.14% of the outstanding shares have been sold short.
| Short Interest | 6.38M |
| Short Previous Month | 6.25M |
| Short % of Shares Out | 12.14% |
| Short % of Float | 15.83% |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, AVTX had revenue of $59,000 and -$84.74 million in losses. Loss per share was -$5.36.
| Revenue | 59,000 |
| Gross Profit | -39.52M |
| Operating Income | -79.16M |
| Pretax Income | -84.57M |
| Net Income | -84.74M |
| EBITDA | -78.93M |
| EBIT | -79.16M |
| Loss Per Share | -$5.36 |
Balance Sheet
The company has $81.99 million in cash and $328,000 in debt, with a net cash position of $81.67 million or $1.55 per share.
| Cash & Cash Equivalents | 81.99M |
| Total Debt | 328,000 |
| Net Cash | 81.67M |
| Net Cash Per Share | $1.55 |
| Equity (Book Value) | 68.32M |
| Book Value Per Share | 2.77 |
| Working Capital | 77.23M |
Cash Flow
| Operating Cash Flow | -59.69M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 226,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -59.69M |
| FCF Per Share | -$1.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | -134,164.41% |
| Pretax Margin | -143,340.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -131.04% |
| Shareholder Yield | -131.04% |
| Earnings Yield | -8.86% |
| FCF Yield | -6.24% |
Analyst Forecast
The average price target for AVTX is $45.25, which is 149.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.25 |
| Price Target Difference | 149.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 29, 2023. It was a reverse split with a ratio of 1:240.
| Last Split Date | Dec 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:240 |
Scores
AVTX has an Altman Z-Score of -4.8 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.8 |
| Piotroski F-Score | 1 |